LIGAND PHARMACEUTICALS INCORPORATED Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $78.68 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $80.51, a 8.36% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $74.30, a 43.41% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $51.81.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $64.73, a 271.58% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $74.04, a 22.10% increase from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $60.64, a 32.32% increase from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $45.83.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $54.28, a 155.32% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 10 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $78.68 10-Q · filed 2026-08-07 | ||||||
| 2026-03-31 | $80.51 10-Q · filed 2026-05-08 | ||||||
| 2025-12-31 | $74.04 10-K · filed 2026-02-27 | ||||||
| 2025-09-30 | $72.78 10-Q · filed 2025-11-07 | ||||||
| 2025-06-30 | $69.16 10-Q · filed 2025-08-08 | ||||||
| 2025-03-31 | $74.30 10-Q · filed 2025-05-09 | ||||||
| 2024-12-31 | $60.64 10-K · filed 2026-02-27 | ||||||
| 2024-09-30 | $59.07 10-Q · filed 2024-11-08 | ||||||
| 2024-06-30 | $53.23 10-Q · filed 2024-08-07 | ||||||
| 2024-03-31 | $51.81 10-Q · filed 2024-05-08 | ||||||
| 2023-12-31 | $45.83 10-K · filed 2026-02-27 | ||||||
| 2023-09-30 | $44.03 10-Q · filed 2023-11-09 | ||||||
| 2022-12-31 | $30.24 10-K · filed 2025-02-28 | ||||||
| 2022-10-31 | $38.56 10-K · filed 2025-02-28 | ||||||
| 2021-12-31 | $54.28 10-K · filed 2024-02-29 | ||||||
| 2020-12-31 | $21.26 10-K · filed 2023-02-28 | ||||||
| 2019-12-31 | $23.65 10-K · filed 2022-02-28 | ||||||
| 2018-12-31 | $55.24 10-K · filed 2021-02-24 | ||||||
| 2018-06-30 | $61.78 10-Q · filed 2018-08-08 | ||||||
| 2018-03-31 | $64.73 10-Q · filed 2018-05-09 | ||||||
| 2017-12-31 | $31.58 10-K · filed 2018-03-01 | ||||||
| 2017-09-30 | $31.85 10-Q · filed 2017-11-09 | ||||||
| 2017-06-30 | $29.11 10-Q · filed 2017-08-09 | ||||||
| 2017-03-31 | $17.42 10-Q · filed 2017-05-09 | ||||||
| 2016-12-31 | $38.08 10-K · filed 2017-02-28 | ||||||
| 2016-09-30 | $34.65 10-Q · filed 2016-11-14 | ||||||
| 2016-06-30 | $30.73 10-Q · filed 2016-11-14 | ||||||
| 2016-03-31 | $23.00 10-Q · filed 2016-11-14 | ||||||
| 2015-12-31 | $26.55 10-K · filed 2016-11-14 | ||||||
| 2015-09-30 | $24.43 10-Q · filed 2015-11-09 | ||||||
| 2015-06-30 | $25.58 10-Q · filed 2015-08-05 | ||||||
| 2015-03-31 | $18.35 10-Q · filed 2015-05-11 | ||||||
| 2014-12-31 | $15.71 10-K · filed 2015-02-23 | $14.60 10-K · filed 2014-12-01 | |||||
| 2014-09-30 | $15.43 10-Q · filed 2014-10-31 | ||||||
| 2014-06-30 | $15.72 10-Q · filed 2014-08-05 | ||||||
| 2014-03-31 | $15.73 10-Q · filed 2014-05-07 | ||||||
| 2013-12-31 | $14.60 10-K/A · filed 2014-12-12 | ||||||
| 2013-09-30 | $14.76 10-Q · filed 2013-11-08 | ||||||
| 2013-06-30 | $15.31 10-Q · filed 2013-08-01 | ||||||
| 2013-03-31 | $13.96 10-Q · filed 2013-05-08 | ||||||
| 2012-12-31 | $11.31 10-K/A · filed 2014-12-12 | ||||||
| 2012-09-30 | $9.96 10-Q · filed 2012-11-14 | ||||||
| 2012-06-30 | $10.25 10-Q/A · filed 2012-11-14 | ||||||
| 2011-12-31 | $9.51 10-K/A · filed 2014-12-12 |